Soricimed Biopharma appointed Dr. Siqing Fu, a North American leader in cancer research, to its scientific advisory board. Dr. Fu has more than 20 years of experience in cancer research and is currently a professor in...

Closely-held Ripple Therapeutics appointed Jonathan Talamo, M.D., currently a member of the board, to be chairman. Dr. Talamo is internationally known as an experienced surgeon and thought leader in ophthalmology, with...

Kumaraguru Raja, Ph.D., joined ROTH Capital Partners healthcare research team, as managing director, senior research analyst covering biotechnology. His research coverage is expected to include micro-cap and small-cap...

Verséa Holdings appointed Rob Sambursky, M.D., as president to support its corporate strategy and operations as well as lead the company’s expansion into the ophthalmic market. Verséa recently launched a new business...

Zymeworks (NYSE:ZYME) is strengthening its senior leadership team with the appointment of Paul Moore, Ph.D., as chief scientific officer, reporting directly to the CEO, effective July 18. Dr. Moore brings more than 25...

Rodney Ouellette Soricimed Biopharma appointed one of Atlantic Canada’s leading cancer researchers, Rodney Ouellette, M.D. and Ph.D., to its scientific advisory board. “Rodney has dedicated his life’s work...

Frank Michalargias Closely-held Soricimed Biopharma, an oncology drug developer, appointed healthcare industry veteran Frank Michalargias as CFO.  In a finance and operations leadership career spanning more than 25...

After an absence of five years, Eric Cheng has rejoined Maxim Group as a senior managing director and head of healthcare investment banking. Mr. Cheng held similar titles at Maxim between 2011 and 2017. Mr. Cheng brings...